Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern
Recommend:
0

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago LAPOLLA : Releases Full Year 2013 Financial Results
<1m ago MKT ALL : The Marketing Alliance Releases 3rd Quarter Fiscal 2014 Financial Results
<1m ago BUCKEYE PARTNERS : JP Energy Partners Names Jeremiah Ashcroft as EVP and COO
<1m ago VOXELJET AG : Prices Public Offering of ADSs
<1m ago Covidien Voluntarily Recalls Its Pipeline Embolization Device, Alligator Retrieval Device
<1m ago Hitachi High-Tech Gets Intel's Supplier Continuous Quality Improvement Award
<1m ago CRA : Charles River Associates Sets Date to Release 1st Quarter FY 2014 Financial Results
<1m ago UQM TECHNOLOGIES : William Rankin to Retire; Donald Vanlandingham Named New Chairman
<1m ago Shaw Communications Declares Monthly Dividends
<1m ago FUJITSU : Certifies Jeda Network's Virtual SAN Controller for Networking with Its Eternus Storage Arrays
Latest news
Advertisement
Hot News 
THE COCA-COLA COMPANY : Wave Systems Corp. Expands Relationship with Micron Technology; Best Buy U.S. Retail Stores President Steps Down
HIGHPOWER : Highppower will attend the 24th China International Bicycle Fair Booth NO.: W5-0025
CT ENVIRONMENTAL : CTEG granted sludge treatment services contract
SCHNEIDER ELECTRIC : Hot or cold air containment? That's the data centre decision
GEA AKTIENGESELLSCHAFT : GEA sells the segment Heat Exchangers (DGAP Adhoc)
Most Read News
1d ago INTEL : quarterly net beats Street, CEO talks up tablets
1d ago YAHOO : sees flat second-quarter as revenue growth remains elusive
1d ago PAN AFRICAN RESOURCES : Karume Day and Rwanda Genocide Day
1d ago Yahoo's growth anemic as turnaround chugs along
1d ago BLACKROCK : CEO Fink's pay totaled 13.6 million pounds in 2013
Most recommended articles
1d ago Asian shares offer muted cheer to China growth
1d ago Weak miners dent FTSE as Ukraine, earnings jitters persist
6d agoDJCarrefour Sales Grow at Fastest Pace in Two Years
37m agoDJCHINA STATISTICS BUREAU : 1st-Quarter Growth in 'Reasonable Range'
38m ago CHINESE YUAN : A Better 1Q GDP Outcome for Reassurance or Stimulus Motivation?
Dynamic quotes  
ON
| OFF